Chemoresistance in Pancreatic Cancer
- PMID: 31514451
- PMCID: PMC6770382
- DOI: 10.3390/ijms20184504
Chemoresistance in Pancreatic Cancer
Abstract
Pancreatic ductal adenocarcinoma (PDAC), generally known as pancreatic cancer (PC), ranks the fourth leading cause of cancer-related deaths in the western world. While the incidence of pancreatic cancer is displaying a rising tendency every year, the mortality rate has not decreased significantly because of late diagnosis, early metastasis, and limited reaction to chemotherapy or radiotherapy. Adjuvant chemotherapy after surgical resection is typically the preferred option to treat early pancreatic cancer. Although 5-fluorouracil/leucovorin with irinotecan and oxaliplatin (FOLFIRINOX) and gemcitabine/nab-paclitaxel can profoundly improve the prognosis of advanced pancreatic cancer, the development of chemoresistance still leads to poor clinical outcomes. Chemoresistance is multifactorial as a result of the interaction among pancreatic cancer cells, cancer stem cells, and the tumor microenvironment. Nevertheless, more pancreatic cancer patients will benefit from precision treatment and targeted drugs. Therefore, we outline new perspectives for enhancing the efficacy of gemcitabine after reviewing the related factors of gemcitabine metabolism, mechanism of action, and chemoresistance.
Keywords: FOLFIRINOX; PDAC; chemoresistance; gemcitabine; pancreatic cancer.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6770382/bin/ijms-20-04504-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6770382/bin/ijms-20-04504-g002.gif)
Similar articles
-
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16. Lancet Gastroenterol Hepatol. 2021. PMID: 33338442 Clinical Trial.
-
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.Adv Biol Regul. 2018 May;68:77-87. doi: 10.1016/j.jbior.2017.11.007. Epub 2017 Nov 22. Adv Biol Regul. 2018. PMID: 29221990 Review.
-
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.Eur J Cancer. 2022 Oct;174:102-112. doi: 10.1016/j.ejca.2022.06.042. Epub 2022 Aug 18. Eur J Cancer. 2022. PMID: 35988408
-
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.BMC Cancer. 2018 Dec 29;18(1):1298. doi: 10.1186/s12885-018-5183-y. BMC Cancer. 2018. PMID: 30594153 Free PMC article.
-
Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.Crit Rev Oncog. 2019;24(2):199-212. doi: 10.1615/CritRevOncog.2019031641. Crit Rev Oncog. 2019. PMID: 31679214 Review.
Cited by
-
Modulation of Epithelial-Mesenchymal Transition Is a Possible Underlying Mechanism for Inducing Chemoresistance in MIA PaCa-2 Cells against Gemcitabine and Paclitaxel.Biomedicines. 2024 May 3;12(5):1011. doi: 10.3390/biomedicines12051011. Biomedicines. 2024. PMID: 38790973 Free PMC article.
-
Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.Front Immunol. 2024 May 2;15:1383978. doi: 10.3389/fimmu.2024.1383978. eCollection 2024. Front Immunol. 2024. PMID: 38756774 Free PMC article. Review.
-
Solute carrier family 16 member 1 as a potential prognostic factor for pancreatic ductal adenocarcinoma and its influence on tumor immunity.J Gastrointest Oncol. 2024 Apr 30;15(2):730-746. doi: 10.21037/jgo-24-147. Epub 2024 Apr 28. J Gastrointest Oncol. 2024. PMID: 38756638 Free PMC article.
-
NEMO/NF-κB signaling functions as a double-edged sword in PanIN formation versus progression to pancreatic cancer.Mol Cancer. 2024 May 16;23(1):103. doi: 10.1186/s12943-024-01989-x. Mol Cancer. 2024. PMID: 38755681 Free PMC article.
-
Differentially expressed genes associated with high metabolic tumor volume served as diagnostic markers and potential therapeutic targets for pancreatic cancer.J Transl Med. 2024 May 13;22(1):453. doi: 10.1186/s12967-024-05181-z. J Transl Med. 2024. PMID: 38741142 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical